CP-690: Phase II data

Data from a 3-month, double-blind, placebo-controlled, Japanese Phase II trial (Study A3921039) in 136 patients showed that 1, 3, 5 and 10 mg doses of CP-690,550 plus methotrexate met the primary endp...